Core Viewpoint - Qianjin Pharmaceutical (600479.SH) reported a total operating revenue of 3.635 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders reached 288 million yuan, marking a year-on-year increase of 24.74% [1] - The net profit after deducting non-recurring gains and losses was 261 million yuan, up 19.48% year-on-year [1] - Basic earnings per share stood at 0.6414 yuan [1] Revenue and Profit Growth - The primary reasons for the company's revenue growth include stable revenue from core industrial enterprises and improved profitability [1] - The acquisition of stakes in two subsidiaries, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (28.92% stake) and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. (68% stake), contributed to the financial results as they were consolidated under the new ownership percentages starting in October and November 2025, respectively [1]

Group 1 - The company reported a total operating revenue of 3.635 billion yuan for the fiscal year 2025, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders of the listed company was 288 million yuan, showing a year-on-year increase of 24.74% [1] - The basic earnings per share were 0.6414 yuan [1]

Financial Performance - Total operating revenue for 2025 reached ¥3,634,578,070.78, a slight increase of 0.13% compared to ¥3,629,804,492.14 in the previous year[4] - Operating profit rose to ¥440,507,648.01, marking a significant increase of 32.64% from ¥332,110,652.19 year-on-year[4] - Net profit attributable to shareholders was ¥287,836,838.39, reflecting a growth of 24.74% compared to ¥230,756,619.25 in the prior year[4] - The company reported a net profit excluding non-recurring gains and losses of ¥261,435,059.34, a 19.48% increase from ¥218,815,693.34[4] Asset and Equity Growth - Total assets increased by 10.71% to ¥5,044,504,252.10 from ¥4,556,298,077.73 at the beginning of the period[4] - Shareholders' equity attributable to the parent company rose by 23.06% to ¥3,030,178,541.36 from ¥2,462,279,280.07[4] Earnings and Returns - Basic earnings per share improved to ¥0.6414, an increase of 14.97% from ¥0.5579[4] - The weighted average return on net assets increased to 9.73%, up by 0.19 percentage points from 9.54%[4] Acquisitions - The company acquired 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% of Hunan Qianjin Xieli Pharmaceutical Co., Ltd., which began contributing to consolidated results in October and November 2025, respectively[5] Risk Advisory - The company advises investors to be aware of potential risks as the reported financial data is preliminary and subject to change in the final annual report[6]

Core Insights - The company reported a total operating revenue of 3.635 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 0.13% [1] - The net profit reached 288 million yuan, showing a significant year-on-year increase of 24.74% [1] - The growth in performance is attributed to stable revenue growth from core industrial enterprises and improved profitability [1] Revenue and Profit Analysis - Total operating revenue for 2025 was 3.635 billion yuan, with a slight increase of 0.13% compared to the previous year [1] - Net profit for the same period was 288 million yuan, marking a substantial increase of 24.74% year-on-year [1] Strategic Acquisitions - The company acquired a 28.92% stake in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and a 68% stake in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. [1] - These acquisitions were consolidated into the financial statements starting from October and November 2025, respectively [1]

Group 1 - The core viewpoint of the article is that Qianjin Pharmaceutical has reported its performance for the fiscal year 2025, showing modest growth in revenue and significant growth in net profit [1] Group 2 - The company achieved an operating income of 3.635 billion yuan, representing a year-on-year increase of 0.13% [1] - The net profit attributable to shareholders of the listed company was 288 million yuan, reflecting a year-on-year growth of 24.74% [1] - The basic earnings per share were 0.64 yuan, which is a year-on-year increase of 14.97% [1]

Group 1 - The board of directors of Zhuzhou Qianjin Pharmaceutical Co., Ltd. received a resignation letter from Mr. Xie Aiwei, who will continue to serve as the deputy general manager after resigning from the board due to adjustments in the company's governance structure [1] - Mr. Xie Aiwei's resignation will not result in the board falling below the legal minimum number of members, and his resignation is effective upon delivery to the board [1] - The company expresses gratitude for Mr. Xie Aiwei's contributions during his tenure as a director, highlighting his diligence and important role in corporate governance [1] Group 2 - The company held a staff representative meeting on February 5, 2026, to elect Mr. Luo Yong as the employee director of the 11th board of directors, following the procedures outlined in relevant laws and regulations [2] - Mr. Luo Yong meets the qualifications and conditions for serving as a director as per the Company Law and the company's articles of association, with his term starting from the approval date of the staff representative meeting until the end of the 11th board's term [2] - After the election of the employee director, the total number of directors who are also senior management and employee representatives does not exceed half of the total number of directors, complying with legal and regulatory requirements [2]

Group 1 - The resignation of Mr. Xie Aiwei from the board of directors is due to the company's governance structure adjustment, but he will continue to serve as the deputy general manager [2] - The resignation will not result in the board falling below the legal minimum number of members, and it takes effect upon delivery to the board [2] - The company expresses gratitude for Mr. Xie Aiwei's contributions during his tenure as a director [2] Group 2 - The company held a staff representative meeting on February 5, 2026, to elect Mr. Luo Yong as the employee director of the 11th board of directors [2] - The election process complied with relevant laws and regulations, and Mr. Luo Yong meets the qualifications for the position [2][3] - The total number of directors who are also senior management or employee representatives does not exceed half of the total board members, in accordance with legal and regulatory requirements [3]

（文章来源：证券日报） 证券日报网讯 2月5日，千金药业发布公告称，公司董事会收到董事谢爱维先生因公司治理结构调整提 交的书面辞职报告，其辞去董事职务后继续担任副总经理；同日公司召开职工代表大会，无记名投票选 举罗勇先生为第十一届董事会职工董事，任期自2026年2月5日职工代表大会审议通过之日起至第十一届 董事会届满之日止。 ...

证券代码：600479 证券简称：千金药业 公告编号：2026-005 株洲千金药业股份有限公司 关于董事辞职暨选举职工董事公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事辞职情况 株洲千金药业股份有限公司（以下简称"公司"）董事会于近日 收到公司董事谢爱维先生提交的书面辞职报告。因公司治理结构调整， 谢爱维先生申请辞去公司董事职务，辞职后谢爱维先生继续担任公司 副总经理职务。 根据《公司法》及《公司章程》等有关规定，谢爱维先生辞职不 会导致公司董事会成员低于法定最低人数，其辞职报告自送达董事会 之日起生效。 谢爱维先生在担任公司董事期间，恪尽职守、勤勉尽责，在公司 治理、规范运作等方面发挥了重要作用，公司及董事会对谢爱维先生 在任职董事期间所作的辛勤工作和贡献表示衷心感谢！ 二、选举职工董事情况 公司于 2026 年 2 月 5 日召开职工代表大会，会议的召集和召开 程序符合《公司法》等法律法规、行政部门规章、规范性文件和《公 司章程》的有关规定。 根据《公司职工代表大会制度》，公司采用无记名投票方式选举 罗勇 ...

Industry Overview - The gynecological medication industry encompasses drugs for the prevention, diagnosis, and treatment of gynecological diseases, including traditional hormone therapies, antibiotics, analgesics, and immunomodulators [1][3] - The market for gynecological medications in China has shown rapid growth, with the market size increasing from 27.735 billion yuan in 2012 to an estimated 56.137 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 6.05% [1][9] - By 2025, the market size is projected to reach approximately 59.53 billion yuan, driven by increasing awareness of women's health and societal emphasis on female health [1][9] Market Dynamics - The prevalence of gynecological diseases among adult women in China is high, with an estimated incidence rate between 40% and 70%, including conditions such as tumors, cysts, reproductive-related diseases, and gynecological inflammation [6] - The rise in gynecological disease rates and the growing health consciousness among women are contributing to the steady expansion of the gynecological medication market [6] Industry Chain - The gynecological medication industry chain consists of upstream raw materials, intermediates, and pharmaceutical equipment; midstream production; and downstream distribution through pharmacies, hospitals, and e-commerce platforms [6][7] Key Companies - Notable companies in the gynecological medication sector include Qianjin Pharmaceutical, Tongrentang, Kangyuan Pharmaceutical, Jiuzhitang, Yunnan Baiyao, and others, which are focusing on R&D and product differentiation [10][11] Development Trends - Future product development in gynecological medications is expected to shift towards precision and individualized treatment, utilizing diagnostic technologies to enhance treatment efficacy and reduce side effects [12] - Innovations in drug formulations and delivery methods will improve patient compliance and experience, with a focus on long-acting, user-friendly options [13] - The role of gynecological medication companies is evolving from mere drug suppliers to providers of comprehensive health management solutions for women throughout their life stages [14]